Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment
esmo - Findings from the MajesTEC-9 study
AI Summary: Clinical data show teclistamab significantly improves survival for patients with multiple myeloma after one to three prior therapies. Those results have ignited discussions about moving the bispecific antibody earlier in treatment algorithms and prompted labs and clinicians to reassess sequencing strategies across relapsed and refractory myeloma.
Related Stories
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 27 days
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 2 months
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 4 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 4 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 4 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 5 months
Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supplements, Healthcare Finance, Zoonotic Disease, Supply Chain and look for the RSS link.
StackHealth Time Machine